Today, VINNOVA announced that BioArctic Neuroscience AB was granted 1.9 million SEK for development of its proprietary product with the indication Treatment of Traumatic Spinal Cord Injury.
VINNOVA is The Swedish Governmental Agency for Innovation Systems that supports research and development work of the highest quality. BioArctic is driving the development of a new treatment for traumatic Spinal Cord Injury together with The Department of Technical Sciences, Section of Applied Material Sciences, Uppsala University and The Department of Clinical Neuroscience, Division of Clinical CNS Research, Karolinska Institutet.
The product under development is a biodegradable device with a growth factor, which will promote and guide nerve growth in the spinal cord and restore function. During a neurosurgical procedure the injured spinal cord will be replaced by the product.
Currently, there are 2.5 million victims suffering from Spinal Cord Injury, which is a devastating condition with loss of motor function and sensibility below the injured segment. Today, there are no available treatments for Spinal Cord Injury.